Aprepitant and Fosaprepitant

What is Aprepitant and Fosaprepitant?

Aprepitant and Fosaprepitant are two closely related pharmaceutical ingredients primarily used as powerful antiemetic drugs. Their main role is to prevent nausea and vomiting, particularly that induced by chemotherapy or surgery. Aprepitant is available in oral forms (capsules), while Fosaprepitant is an intravenous prodrug that converts to Aprepitant in the body, offering a convenient option for patients requiring immediate relief or unable to take oral medication.

These medications belong to a specific class of drugs known as NK1 receptor antagonists. They are crucial components in modern antiemetic regimens, significantly improving the quality of life for patients undergoing treatments that often cause severe gastrointestinal distress. Their primary use is to prevent chemotherapy-induced nausea and vomiting (CINV). Common brand names include Emend (for Aprepitant) and Emend for injection (for Fosaprepitant), and they are typically used in combination with other antiemetic agents like corticosteroids and serotonin 5-HT3 receptor antagonists.

How Does it Work?

The mechanism of action for Aprepitant and Fosaprepitant revolves around blocking the Neurokinin-1 receptor (NK1 receptor). This receptor is found in various parts of the brain and gastrointestinal tract, including key areas involved in the vomiting reflex. The natural ligand for the NK1 receptor is Substance P, a neuropeptide that plays a significant role in transmitting emetic signals.

By binding to and blocking the NK1 receptors, Aprepitant and Fosaprepitant prevent Substance P from activating these receptors. This blockade effectively inhibits the emetic signaling pathway, thereby preventing both acute and delayed phases of CINV. Unlike many other antiemetics that primarily target the acute phase, NK1 receptor antagonists are particularly effective at preventing delayed CINV, which can occur days after chemotherapy. Their long duration of action contributes to sustained antiemetic protection, making them highly valuable in comprehensive antiemetic protocols.

Medical Uses

The primary medical use of Aprepitant and Fosaprepitant is the prevention of CINV. This includes both the acute phase (within 24 hours of chemotherapy) and the delayed phase (24 hours to 5 days after chemotherapy). They are indicated for use with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens. Due to their efficacy, they are often included in standard antiemetic guidelines alongside 5-HT3 receptor antagonists and corticosteroids.

Beyond CINV, oral Aprepitant also has an indication for the prevention of post-operative nausea and vomiting (PONV). This condition can be a significant concern for patients undergoing surgery, leading to discomfort and prolonged hospital stays. By targeting the NK1 receptor, Aprepitant provides an effective prophylactic option for patients at high risk of developing PONV. It is important to note that these medications are preventative and should be administered before the onset of nausea and vomiting, typically prior to the chemotherapy session or surgical procedure.

Dosage

The dosage of Aprepitant and Fosaprepitant varies depending on the indication and the specific regimen. For the prevention of CINV with highly emetogenic chemotherapy:

• Oral Aprepitant: Typically administered as a 3-day regimen. On Day 1, a single 125 mg dose is taken approximately one hour before chemotherapy. On Day 2 and Day 3, a single 80 mg dose is taken once daily in the morning.
• Intravenous Fosaprepitant: A single 150 mg dose is given intravenously over 20-30 minutes on Day 1, approximately 30 minutes before chemotherapy. This single dose can replace the oral Aprepitant on Day 1 and covers the antiemetic needs for Days 1-3.

For the prevention of PONV, oral Aprepitant is administered as a single 40 mg dose within 3 hours prior to induction of anesthesia. Dosage adjustments may be necessary for patients with severe hepatic impairment, though generally, no dose adjustment is recommended for mild to moderate hepatic impairment. It is crucial to follow the precise instructions of a healthcare professional.

Side Effects

Like all medications, Aprepitant and Fosaprepitant can cause side effects, although not everyone experiences them. Most side effects are mild to moderate and temporary. Common side effects include:

• Fatigue or weakness
• Dizziness
• Headache
• Hiccups
• Diarrhea or constipation
• Dyspepsia (indigestion)
• Abdominal pain
• Loss of appetite

Less common but potentially more serious side effects may include allergic reactions (e.g., rash, itching, swelling of the face/tongue/throat, severe dizziness, trouble breathing), which require immediate medical attention. For Fosaprepitant, infusion site reactions (e.g., pain, redness, swelling at the injection site) can occur. Patients should report any persistent, bothersome, or severe side effects to their doctor or pharmacist promptly. The benefits of these medications in preventing severe nausea and vomiting often outweigh the risks of these side effects, especially in the context of chemotherapy.

Drug Interactions

Aprepitant and Fosaprepitant are known to be moderate inhibitors of the cytochrome P450 3A4 (CYP3A4) enzyme. This means they can affect the metabolism of other drugs that are substrates for this enzyme, potentially increasing their concentrations in the body and leading to enhanced effects or increased side effects. Key drug interactions to be aware of include:

• Corticosteroids: Dexamethasone and methylprednisolone are commonly co-administered. Their doses may need to be reduced when used concurrently.
• Oral Contraceptives: Aprepitant can decrease the effectiveness of hormonal contraceptives. Patients should use an alternative or backup method of contraception during treatment and for up to 28 days after the last dose.
• Warfarin: Aprepitant can affect the metabolism of warfarin, potentially altering INR levels. Close monitoring of INR is recommended.
• Other CYP3A4 Substrates: Caution is advised with other drugs metabolized by CYP3A4, such as certain benzodiazepines (e.g., midazolam, alprazolam), calcium channel blockers (e.g., diltiazem), statins (e.g., simvastatin), and immunosuppressants (e.g., tacrolimus, cyclosporine).

Conversely, strong CYP3A4 inhibitors (e.g., ketoconazole) can increase Aprepitant levels, while strong CYP3A4 inducers (e.g., rifampin) can decrease them. Patients must inform their healthcare provider about all prescription, over-the-counter, and herbal medications they are taking.

FAQ

Q: What is the main difference between Aprepitant and Fosaprepitant?

A: Fosaprepitant is a prodrug of Aprepitant. It's given intravenously and then converted into the active drug, Aprepitant, in the body. Aprepitant itself is typically taken orally.

Q: Can Aprepitant and Fosaprepitant be used to treat existing nausea and vomiting?

A: No, these medications are primarily for prevention. They are most effective when administered before the onset of chemotherapy or surgery.

Q: Are these drugs safe for children?

A: Yes, Aprepitant and Fosaprepitant are approved for use in certain pediatric patients for the prevention of CINV, with specific dosing guidelines.

Q: How long do the effects of Aprepitant and Fosaprepitant last?

A: These drugs have a relatively long duration of action, providing antiemetic protection for several days, which is particularly beneficial for preventing delayed CINV.

Q: Can I take Aprepitant with food?

A: Oral Aprepitant can be taken with or without food. However, always follow your doctor's specific instructions.

Products containing Aprepitant and Fosaprepitant are available through trusted online pharmacies. You can browse Aprepitant and Fosaprepitant-based medications at ShipperVIP or Medicenter.

Summary

Aprepitant and Fosaprepitant are vital medications in the fight against treatment-induced nausea and vomiting. As selective NK1 receptor antagonists, they effectively block the action of Substance P, a key neurotransmitter involved in the emetic reflex. Their unique mechanism of action makes them particularly effective in preventing both acute and delayed CINV, as well as PONV. While generally well-tolerated, awareness of potential side effects and significant drug interactions, especially with CYP3A4 substrates, is crucial. Administered as part of a comprehensive antiemetic regimen, these drugs significantly enhance patient comfort and improve outcomes, allowing individuals to better tolerate their life-saving treatments. Always consult with a healthcare professional to ensure appropriate use and dosage for your specific condition.